Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Completed · Phase 1
Conditions studied: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
In brief
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells are rejected by the body's normal tissues. Transplanting donated cells that have been treated with psoralen may prevent this from happening. PURPOSE: Phase I trial to study the effectiveness of chemotherapy, radiation therapy, and psoralen-treated donor cells in treating patients who are undergoing peripheral stem cell transplantation for hematologic cancer.
Key facts
- Study ID
- NCT00005092
- Run by
- M.D. Anderson Cancer Center
- People needed
- 7
- Starts
- 1999-05-28
- Expected to finish
- 2002-08-28
- Last updated by the study team
- 2018-10-26
Who can join
Age: any, up to 49. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Illinois at Chicago — Chicago, Illinois, United States
- Washington University Barnard Cancer Center — St Louis, Missouri, United States
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.